Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens

E Wohlfarth, F Deuchert, S G Gatermann, P G Higgins, Y Pfeifer, N Pfennigwerth, H Seifert, G Werner, Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Infection Therapy · 2026

Read Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens by E Wohlfarth, F Deuchert, S G Gatermann, P G Higgins, Y Pfeifer, N Pfennigwerth, H Seifert, G Werner, Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Infection Therapy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13243917.txt.

Description

E. Wohlfarth and colleagues updated a head-to-head lab comparison of five modern antibiotics against drug-resistant Gram-negative bacteria. Their study appeared in JAC-Antimicrobial Resistance in 2026. The panel covered 401 clinical isolates collected in Germany in 2019 and 2020. Cefiderocol, a drug that smuggles itself into bacteria through their iron gates, faced four rival combination drugs, with resistance genes checked by sequencing.

Cefiderocol held up best. Against Pseudomonas, its resistance rate sat under two percent, while the rivals failed against a fifth to two-fifths of isolates. Against two other problem germs, the dose needed to stop growth was many times lower than for every rival. A commercial test kit for the drug was also checked against the reference method. The authors conclude that cefiderocol's activity against these problem pathogens exceeds the combinations tested. For hospitals facing the toughest resistant infections, that margin matters.

Catalog record

CREATORE Wohlfarth, F Deuchert, S G Gatermann, P G Higgins, Y Pfeifer, N Pfennigwerth, H Seifert, G Werner, Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Infection Therapy
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13243917

Browse the full library · About the Tower of Babel